**WFNR SPECIAL INTEREST GROUP ANNUAL REPORT**

|  |  |
| --- | --- |
| Name of Special Interest Group  |  The WFNR Neuropathic Pain SIG |
| ChairEmail |  Marta ImamuraMarta.imamura@fm.usp.br |
| Co-Chair(s) where applicable  |  Witsanu Kumthornthip, Thailand (wkumthornthip@yahoo.com)Secretary: Reynaldo Rey-Matias, The Philippines (drreymatias@gmail.com) |
| Number of Members   |  `10 |
| Key objectives and action plan   | **Key objectives:*** Increase awareness of the relevance of neuropathic pain in the rehabilitation of people with stroke, spinal cord injuries, traumatic brain injuries, peripheral neuropathies, multiple sclerosis
* Develop best practice guidelines
* Collaboration with synergic SIGs

**Action Plan:**MembershipEducationClinical UpdatesCollaborative actions with synergic SIGsCollaboration with other organizations: ISPRM, IASP   |
| Activities during previous 12 months     |  **SIG activities were held in 2021**1. Leadership: New SIG vice chair: Witsanu Kumthornthip, Thailand
2. Membership: new SIG member for a global representation (Europe): Dr Michel Fataki Likale (Resident in Physical Medicine and Rehabilitation, Clinique Romande de Réadaptation SUVA, Switzerland)
3. Education:
	1. Organized and prepared online educational program on updates on evaluation and management of neuropathic pain
	2. Retrieved and updated educational materials from previous WFNR educational scientific programs including:
		1. Clinical updates on neuropathic pain;
			1. Introduction and Definition, Incidence, Etiology and Pathophysiology
			2. Evaluation and Diagnosis
			3. Treatment
		2. Neuropathic pain in selected rehabilitation related health conditions
			1. Stroke
			2. Spinal Cord Injuries
			3. Neuromuscular Disorders (Multiple Sclerosis and Parkinson’s)
			4. Peripheral neuropathy injuries and illnesses
			5. Cerebral palsy
		3. Complimentary interventions for neuropathic pain
			1. Biofeedback
			2. TENS
			3. Acupuncture
			4. Hypnosis
		4. Overview of the endocannabinoid system
			1. The rationale uses of cannabinoids in pain
4. Symposium on Pain Management during the Indian Federation of Neurorehabilitation, and the Asia Oceanian Congress of Neurorehabilitation 2021, under the theme: Holistic Rehabilitation – From hospital to community. Topics of the symposium included Neuropathic and Nociplastic Pain, Central Poststroke Pain, New trends in neurorehabilitation: the relevance of nociplastic pain.
5. International Association for the Study of Pain -IASP’s COVID-19 & Pain Virtual Program on September 8, 2021: “Maintaining a Pain Management Regime with Managing COVID-19.”
6. Fostered potential collaborative activities with other SIGs: “Neuropathic pain: evidence-based approach for clinical practice: the role of brain modulation”, together with the Brain modulation for neuro recovery SIG chair, Prof Wayne Feng.
7. Initiated communication for collaboration with the International Society of Physical and Rehabilitation Medicine PAIN SIG.
 |
| Proposed activities   |  **Proposed activities for 2022:**1. Membership: active recruitment of new SIG members for a global representation
2. Education:
	1. Deliver the online educational program on updates on evaluation and management of neuropathic pain
	2. Deliver the updated educational materials from previous WFNR educational scientific programs including:
		1. Clinical updates on neuropathic pain;
			1. Introduction and Definition, Incidence, Etiology and Pathophysiology
			2. Evaluation and Diagnosis
			3. Treatment
		2. Neuropathic pain in selected rehabilitation related health conditions
			1. Stroke
			2. Spinal Cord Injuries
			3. Neuromuscular Disorders (Multiple Sclerosis and Parkinson’s)
			4. Peripheral neuropathy injuries and illnesses
			5. Cerebral palsy
		3. Complimentary interventions for neuropathic pain
			1. Biofeedback
			2. TENS
			3. Acupuncture
			4. Hypnosis
		4. Overview of the endocannabinoid system
			1. The rationale uses of cannabinoids in pain
3. Clinical Updates:
	1. Organize the online forum on Pain in COVID-19:
		* 1. Pivotal role of neuro-immune and inflammation interactions
			2. Main symptoms
			3. Predictive factors from the acute phase: what have we learned
			4. Management rational
			5. Future directions
	2. Botulinum toxin and neuropathic pain: evidence-based approach for clinical practice
	3. Neuropathic pain: evidence-based approach for clinical practice: the role of brain modulation
4. Establish collaboration with other SIGs according to the synergies identified in the adopted WFNR SIG framework and synergies: Submission of a joint proposal for a session during the WCNR 2022: Mild and severe brain injury; multiple sclerosis and dementia; spinal cord injury, stroke rehabilitation; alternative medicine; botulinum toxin and spasticity; brain modulation for neuro-recovery
5. Establish collaboration action plans with other International Societies: ISPRM
 |
| Publications | None in 2021. |

Please send to Tracey Mole, WFNR Executive Director, traceymole@wfnr.co.uk